Endpoints News 19 déc. 2025 Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail
Endpoints News 19 déc. 2025 Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration
Endpoints News 18 déc. 2025 Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths
Endpoints News 18 déc. 2025 After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset
Endpoints News 18 déc. 2025 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Endpoints News 18 déc. 2025 Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis